首页 | 本学科首页   官方微博 | 高级检索  
   检索      

西比灵联合NGF对脑出血患者的NIHSS、ADL评分及血肿体积改善效果
引用本文:王红娟,宋慧群,张姗姗,司翠平,程文静,张清林.西比灵联合NGF对脑出血患者的NIHSS、ADL评分及血肿体积改善效果[J].现代生物医学进展,2021(17):3320-3324.
作者姓名:王红娟  宋慧群  张姗姗  司翠平  程文静  张清林
作者单位:济宁市第一人民医院神经内科 山东 济宁 272000;济宁医学院附属医院 山东 济宁 272001
基金项目:山东省自然科学基金项目(ZR2015HL039)
摘    要:摘要 目的:研究西比灵联合神经生长因子(NGF)对脑出血患者的NIHSS、ADL评分及血肿体积影响。方法:研究对象选取我院2015年9月到2016年10月间收治的脑出血98例,采用随机数字法分为2组,每组各49例。对照组接受常规基础性治疗,在此基础上,研究组患者口服西比灵联合肌肉注射NGF治疗。比较两组患者的治疗总有效率,同时比较血肿、水肿带体积、神经功能缺损量表(NIHSS)、日常生活能力量表(ADL)评分、神经源性营养因子(BDNF)、单核细胞趋化蛋白-1(MCP-1)、神经元特异性烯醇化酶(NSE)水平变化情况及不良反应发生情况。结果:治疗后,两组总有效率比较差异显著(P<0.05);治疗前,研究组和对照组血肿体积、水肿带体积比较无显著差异;治疗后,研究组和对照组血肿体积、水肿带体积随着时间的推移而降低,且研究组均低于对照组,差异显著(P<0.05);治疗前,研究组和对照组NIHSS、ADL评分比较无显著差异;治疗后,研究组和对照组NIHSS随着时间的推移而降低,且研究组均低于对照组,ADL评分随着时间的推移而升高,且研究组高于对照组,差异显著(P<0.05);治疗前,研究组和对照组BDNF、MCP-1、NSE比较无显著差异;治疗后,研究组和对照组MCP-1、NSE随着时间的推移而降低,且研究组均低于对照组,BDNF随着时间的推移而升高,且研究组高于对照组,差异显著(P<0.05);两组不良反应比较无效显著差异(P>0.05)。结论:脑出血患者应用西比灵联合NGF效果可靠,可明显减少继发性损伤,且治疗安全性较高,值得在临床推广。

关 键 词:西比灵  NGF  脑出血  NIHSS  ADL  血肿体积
收稿时间:2021/2/5 0:00:00
修稿时间:2021/2/28 0:00:00

Sibeline Combined with NGF on NIHSS in Patients with Cerebral Hemorrhage, Hematoma Volume and ADL Score Improvement Effect
Abstract:ABSTRACT Objective: To study the effect of flunarizine combined with nerve growth factor (NGF) on NIHSS in patients with cerebral hemorrhage, ADL score and volume of hematoma. Methods: 98 cases of cerebral hemorrhage admitted to our hospital from September 2015 to October 2016 were selected as the study subjects, and divided into 2 groups by random number method, 49 cases in each group. Patients in the control group received conventional basic treatment, and patients in the study group received oral sibiline combined with intramuscular injection of NGF on the basis of this treatment. Compare two groups of patients with total effective rate of treatment, at the same time comparative hematoma, edema zone volume, neural function defect scale (NIHSS) scores, daily life ability scale (ADL) score, neurogenic nutrition factor(BDNF), monocyte chemotactic protein 1(MCP 1), neuron specific enolization enzyme (NSE) level changes and adverse reactions occur. Results: After treatment, the total effective rate between the two groups was significantly different (P<0.05). Before treatment, there were no significant differences in hematoma volume and edema zone volume between the study group and the control group. After treatment, the volume of hematoma and edema zone in the study group and the control group decreased with time, and the difference was significant(P<0.05). Before treatment, there were no significant differences in NIHSS and ADL scores between the study group and the control group. After treatment, the NIHSS of the study group and the control group decreased over time, and the ADL score of the study group was higher than that of the control group, and the difference was significant(P<0.05). Before treatment, there were no significant differences in BDNF, MCP-1 and NSE between the study group and the control group. After treatment, MCP-1 and NSE of the study group and control group decreased with time, and both of the study group were lower than the control group, while BDNF increased with time, and the study group was higher than the control group, the difference was significant(P<0.05). There was no significant difference in ADR between the two groups(P>0.05). Conclusion: The effect of sibilin combined with NGF in patients with intracerebral hemorrhage is reliable, which can significantly reduce the secondary injury, and the treatment is safe and worthy of clinical promotion.
Keywords:Sibeline  NGF  NIHSS  ADL  Cerebral hemorrhage  Hematoma volume
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号